[{"id":"9d99d61b-3750-4ca3-9c05-3d81abc8c4b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05617755","created_at":"2022-11-15T14:56:57.758Z","updated_at":"2024-07-02T16:35:05.607Z","phase":"Phase 1","brief_title":"AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05617755","lead_sponsor":"Arsenal Biosciences, Inc.","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • AB-1015"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/29/2022","start_date":" 11/29/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-05-07"}]